Kornimate/medical-research-clean huggingface dataset:
effect of muscle energy technique versus strain-counterstrain on upper trapezius trigger points

Conditions: Trigger Point Pain, Myofascial

Summary: aim of the study to determine the comparative effects of muscle energy technique and strain counter strain in upper trapezius trigger point.

a randomized controlled trial will be conducted after approval of synopsis. to enroll patients purposive sampling technique will be used. patients will be selected according to the pre-defined inclusion and exclusion criteria. the enrolled patients will be allocated into two groups, group a and group b. on group a muscle energy technique will be applied for 30 seconds and repeat 3 to 5 times per on treatment session and group b will be treated with strain counter strain for 20-30 seconds and repeat this process for up to five times. assessment will be done at baseline, 2nd week, 4th week and 6th week of treatment. follow up will be assessed 15 days after completion of treatment protocol. the patients' outcome will be measured by visual analog scale for pain intensity and neck disability index . informed consent will be taken from each patient. statistical package of social sciences software, version 20 will be used for the analysis of data.

Eligibility criteria:
inclusion criteria: 1. participants who are 18 to 34 years old 2. in upper trapezius from 2 weeks had mechanical neck pain and was diagnosed with active myofacial trigger points 3. subjects have to exhibit a tendor point in the upper trapezius muscle either on the left or right side 4. local pain is greater than 3/10 on visual analog scale exclusion criteria: 1. patient with cervical radiculopathy 2. patients with fibromyalgia syndrome 3. patients who had cervical spine surgery 4. patient with myelopathy 5. patients who had myofacial pain therapy

Keywords: muscle energy technique myofascial trigger point upper trapezius strain-counterstrain
metabolic activation with protein-rich formula diet

Conditions: Type 2 Diabetes Mellitus

Summary: formerly, the investigators demonstrated in an uncontrolled proof-of principle study (nct 01680926) that protein-rich meal replacement (prmr) was successful in reducing daily insulin demand, hba1c and weight in type 2 diabetes mellitus (t2dm) patients injecting \>100 ie insulin/day. the aim of the present study was to investigate in a randomized-controlled trial if prmr is also effective in t2dm patients treated with oral antidiabetic medication or insulin. a second part of the study is an open-label registry for persons with type 2 diabetes, who will perform the lifestyle intervention with the stringent diet regime.

type 2 diabetes mellitus (t2dm) patients had been randomized into two groups. during the 1st week the intervention group with stringent diet regime replaced 3 main meals by 50 g prmr (almased-vitalkost, almased wellness gmbh, bienenbüttel, germany) each (=1100 kcal/day). in 2nd-4th week 2 meals were replaced and a protein-rich lunch was allowed. in 5th-12th week only dinner was replaced. the control group with moderate diet regime replaced breakfast and dinner for 4 weeks and then only dinner during the next 8 weeks. clinical parameters were determined at the study center at baseline, after 4, 8 and 12 weeks. primary endpoint was reduction of hba1c, secondary endpoints reduction of weight and antidiabetic medication. in the second part of the study type 2 diabetes patients are included in an open-label reistry and perform the lifestyle intervention with the stringent diet regime.

Eligibility criteria:
inclusion criteria: * type 2 diabetes mellitus * hba1c \> 7,5% * body mass index (bmi) ≥ 27,5 kg/m2 exclusion criteria: * acute infections * severe diseased with hospital stay during the last 3 months * chronic diseases * chemotherapy or cortisone treatment * weight loss of more than 2 kg per week during the last month * smoking cessation during the last 3 months or planned * weight-influencing medication * pregnancy, breast-feeding or lack of contraception * high-level physical activity of more than 1h per day * incompatibility with components of the prmr * participation in an other study during the last 6 months for the open-label registry, the only inclusion criterium is type 2 diabetes.
a study of synthetic human secretin (chirhostim®) administered intravenously to stimulate exocrine pancreas fluid secretion for collection via endoscope and laboratory analysis of dna markers

Conditions: Pancreatic Disease

Summary: the following are the study hypothesis: * secretin administration compared to placebo will result in a statistically significantly greater percentage of collected fluid samples being predominantly of exocrine pancreas origin when samples are duodenal aspirates. * secretin administration compared to placebo will result in a statistically significantly greater percentage of collected fluid samples meeting the minimum specifications for use in the indicated laboratory test of dna mutational analysis.


Eligibility criteria:
inclusion criteria: 1. documented or suspected diagnosis of chronic pancreatitis or suspected diagnosis of pancreatic cancer. 2. undergoing endoscopic procedure. 3. age ≥ 18 years. 4. willing and able to sign informed consent, meeting irb guidelines. 5. willing and able to meet all study requirements and obligations. exclusion criteria: 1. ongoing, active pancreatitis at the time of the procedure. 2. known adverse reaction to secretin. 3. recent (within one month) use of medication that can potentially cause pancreatitis, such as metronidazole, tetracycline, sulfonamides. 4. use of anticholinergic medication within 7 days of study. 5. pregnant women, nursing mothers, or women of childbearing potential not employing appropriate contraception. acceptable methods of birth control are: intrauterine device, implantable progesterone device, progesterone intramuscular injection, oral contraceptive (started at least one month prior to visit 1 and continuing for the duration of the trial), contraceptive patch, condoms with spermicide or abstinence. 6. any medical condition which in the judgment of the principal investigator makes participation of the patient in the study medically unwarranted. 7. known complete obstruction of the pancreatic duct. 8. patients who have received an investigational product/drug or device within 30 days prior to visit 1.

Keywords: genetic end marker
normotensive and hypertensive placental abruptions

Conditions: Abruptio Placentae; Affecting Fetus or Newborn

Summary: placental abruption is a significant cause of both maternal morbidity and neonatal morbidity and mortality. most abruptions accept to be related to a chronic placental disease process. therefore, it is very important to understand these processes. to analyze maternal and neonatal effects of placental abruption(pa) through a novel classification in the presence of hypertension. initial hemoglobin parameters were also compared to predict pregnancy outcomes in addition to hypertension.

objective: we aimed to classify placental abruption according to hypertension status. methods: this retrospective cohort designed study was conducted on 115 pregnant women with placental abruption. the main parameters scanned and recorded from the hospital database and patient medical files. two groups were classified regarding of presence or absence of hypertension (53 hypertensive, 62 normotensive). maternal demographical and clinical characteristics (abdominal pain, vaginal bleeding) were recorded. apgar scores below 5 at 1 and 5 min., fetal or neonatal death, admission and length of stay in neonatal intensive care unit(nicu) were also investigated and compared between the groups.

Eligibility criteria:
inclusion criteria: * spontaneous, * singleton pregnancies * above 25 weeks of gestations with positive fetal cardiac activity exclusion criteria: * multiple gestations, * presence of fetal or maternal infection, * chronic inflammatory diseases or connective tissue disorders * history of myocardial infarction, * thrombosis * history of steroid drug usage.

Keywords: abruptio placenta complete blood count hypertension perinatal outcome. mean platelet volume
efficacy of mobile-delivered sleep restriction therapy for treatment of insomnia disorder: randomised controlled trial

Conditions: Insomnia

Summary: the "sleepfix study" is a clinical trial designed to evaluate the efficacy of mobile-delivered sleep restriction therapy (dbti) in comparison to digital sleep health education (control) for treating insomnia disorder in adults aged 18 and above. the study is conducted entirely online, with 558 participants (279 in each group) and aims to determine the impact of the interventions on insomnia symptom severity, sleep metrics, subjective sleep quality, fatigue, anxiety, depressive symptoms, quality of life, medication usage, and workforce productivity.


Eligibility criteria:
inclusion criteria: * adults aged ≥ 18 years * able to give informed online consent * insomnia severity index ≥ 12 * english fluency * access to a smartphone and willingness/proficiency to use a mobile application exclusion criteria: * shift-workers (at least 2 night shifts a week between the hours of 8 pm to 8 am) * serious medical and/or psychiatric illnesses/disorders * previously diagnosed or suspected/high-risk of undiagnosed sleep disorders (e.g. rem sleep behaviour disorder, restless leg syndrome * currently receiving cognitive behavioural therapy for insomnia (cbt-i) * operators of machinery that require high alertness (e.g. truck drivers, train drivers, pilots, etc) * pregnant women

Keywords: cbti digital cbti insomnia
a comparison study of treatments given to patients with concurrent eating disorder and personality disorder.

Conditions: Eating Disorder; Anorexia Nervosa; Bulimia Nervosa; Personality Disorder

Summary: the aim of this study is to determine whether in-patient treatment is better then intensive out-patient group treatment for patients with concurrent eating disorder and personality disorder.

the main aim of the study is to compare the effects of in-patient treatment with a group based intensive out-patient treatment. it is a randomized controlled comparison study including patients with concurrent eating disorder and personality disorder. 18 patients will receive an in-patient treatment lasting one year. 18 patients will receive intensive out-patient treatment consisting of two-weekly group sessions, lasting one year. personality disorder, eating behavior, symptoms, and function will be followed for two years.

Eligibility criteria:
inclusion criteria: * anorexia nervosa, bulimia nervosa, personality disorder. exclusion criteria: * male, schizophrenia.

Keywords: eating disorders anorexia nervosa bulimia nervosa personality disorders in-patient treatment out-patient treatment group therapy
effect of covid-19 on outcomes of pregnancy

Conditions: Pregnancy Without Complications Except Getting Covid-19 Infection

Summary: to study the effect of getting covid-19 infection during pregnancy on the outcomes of the mother and the fetus including morbidity and mortality


Eligibility criteria:
inclusion criteria: * normal single pregnancy exclusion criteria: * pregnancy with any chronic diseases * multiple pregnancy

Keywords: pregnancy covid-19
genetic study of brain tumors in young children

Conditions: Central Nervous System Tumor, Pediatric

Summary: rationale: genetic studies may help in understanding the genetic processes involved in the development of some types of cancer. purpose: genetic study to understand how genes may be involved in the development of brain tumors in young children.

objectives: * determine the frequency and type of deletions and mutations of the ini1 gene in infants with embryonal central nervous system tumors. * compare the gene expression profiles in infants with atypical teratoid/rhabdoid tumors vs medulloblastoma or primitive neuroectodermal tumor. outline: this is a multicenter study. tumor samples are analyzed by fluorescence in situ hybridization (fish) for deletions of ini1 gene in chromosome band 22q11.2. tumors without demonstration of deletions of ini1 gene by fish are examined by polymerase chain reaction (pcr)-based microsatellite analysis for loss of heterozygosity using markers that map to 22q11.2. dna from tumor tissue is analyzed for mutations in the exons of the ini1 gene. isolated matched normal dna may be analyzed for identification of germline mutations. parental dna may be analyzed to identify inherited germline mutations of the ini1 gene. the patient's physician may receive the results of the genetic testing. the results do not influence the type or duration of treatment. projected accrual: a total of 50 patients will be accrued for this study within 25 months.

Eligibility criteria:
disease characteristics: * histologically confirmed primary intracranial central nervous system tumor * medulloblastoma * primitive neuroectodermal tumor * atypical teratoid/rhabdoid tumor * choroid plexus carcinoma * potential enrollment on pbtc-001 therapeutic protocol patient characteristics: age: * under 3 performance status: * not specified life expectancy: * not specified hematopoietic: * not specified hepatic: * not specified renal: * not specified prior concurrent therapy: biologic therapy: * not specified chemotherapy: * no prior chemotherapy endocrine therapy: * prior steroids allowed radiotherapy: * no prior radiotherapy surgery: * not specified other: * no concurrent investigational agents

Keywords: childhood choroid plexus tumor untreated childhood supratentorial primitive neuroectodermal tumor untreated childhood medulloblastoma childhood atypical teratoid/rhabdoid tumor
combination of psychosocial intervention and slow prosecutions for the treatment of methamphetamine abuse/dependence

Conditions: Amphetamine Abuse; Amphetamine Dependence; Methamphetamine Abuse; Methamphetamine Dependence

Summary: the hospital where this study will be conducted is responsible for the one-year contingency management treatment for methamphetamine drug offenders referred from the yunlin district prosecutors office. completing the one-year treatment is prerequisite for offenders to get slow prosecutions. it is an open-label, parallel-group trial comparing the combination of psychosocial intervention and slow prosecutions with psychosocial intervention alone in treating subjects with methamphetamine dependence study hypothesis 1. psychosocial interventions in combination with slow prosecutions is more effective than psychosocial interventions alone to achieve abstinence for subjects with methamphetamine abuse/dependance. 2. inclusion of telephone reminding before each visit will enhance the retention rate and abstinence rate.


Eligibility criteria:
inclusion criteria: * dsm-iv-tr criteria for amphetamine/methamphetamine abuse or dependence * 18 - 65 years old * for tstsu-n and tstsu-t arms: methamphetamine offenders referred by the yunlin district prosecutors office * for opd arm: psychiatric outpatients referred from the psychiatry clinics in national taiwan university hospital, yunlin branch exclusion criteria: * concurrent use of other illicit substances * co-morbidity with major psychotic disorders (schizophrenia, schizoaffective disorder, other psychotic disorder), mental retardation, acute episodes of major depressive disorder or bipolar affective disorder) or serious personality disorders.

Keywords: amphetamine methamphetamine psychosocial intervention contingency management slow prosecution substance use disorder
happy bob app: a preliminary evaluation of its use in youth with diabetes

Conditions: Type 1 Diabetes

Summary: the goal of this clinical trial is to evaluate the impact of peer support via the happy bob phone app in youth with type 1 diabetes. the main questions it aims to answer are: what is the usability and acceptability of the app? what is the app's efficacy on measures such as treatment adherence and social support? and how are these effects impacted by remote patient monitoring by clinic staff? participants will use the happy bob app for 6 months and will complete a series of surveys at the start, middle, and end of their use of the app. some participants will participate in 2 remote patient monitoring sessions when beginning their use of the app.


Eligibility criteria:
inclusion criteria: diagnosis of type 1 diabetes, use dexcom and smart phone exclusion criteria: non-english speaking
longitudinal evaluation of microbial and host signatures during immunotherapy for lung cancer

Conditions: Lung Cancer

Summary: this study will prospectively collect airway, stool, and blood samples on 80 subjects with lung cancer undergoing immunotherapy. investigators will evaluate airway/stool microbial signatures associated with local (lower airway) and systemic (blood) immune tone.they will then study whether microbiota and/or host signatures predict subjects' response by longitudinal assessment of the progression free survival. they will also repeat sampling after 8 weeks of immunotherapy to expand our mechanistic understanding of the response to treatment.


Eligibility criteria:
inclusion criteria: * adult patients with a diagnosis of advanced stage unresectable non-small cell lung cancer and indication for pd-1 blockade treatment (either as monotherapy or combined with chemotherapy) exclusion criteria: * antibiotic, steroid, or chemotherapy received within the prior month since these are possible confounders that may impact the microbiome and the host immunity. * brain metastasis (as evaluated by mri obtained as part of standard of care staging evaluation) * fev1\<50% predicted * cardiovascular disease (defined as abnormal ekg, known or suspected coronary artery disease or congestive heart failure) * renal disease * coagulopathy * liver disease
a study of pegasys (peginterferon alfa-2a) plus ribavirin in patients with chronic hepatitis c (chc), genotype 2 or 3

Conditions: Hepatitis C, Chronic

Summary: this randomized, parallel arm study will evaluate the efficacy and safety of pegasys (peginterferon alfa-2a) in combination with 2 different doses of ribavirin in patients with chronic hepatitis c, genotype 2 or 3. patients will be randomized to 4 treatment groups receiving pegasys (180 mcg subcutaneously weekly) for either 16 or 24 weeks with one of two doses of ribavirin (400 mg or 800 mg orally daily). the anticipated time on study treatment is 16 or 24 weeks with a 24-week follow-up.


Eligibility criteria:
inclusion criteria: * adult patients, 18-65 years of age * chronic hepatitis c, genotype 2 or 3 * positive hcv rna level in serum at screening (cobas amplicor monitor hcv test) * abdominal sonography within 3 months prior to study start exclusion criteria: * previous interferon and/or pegylated interferon and ribavirin therapy * liver cirrhosis, class b or c (child-pugh) * systemic anti-neoplastic or immunomodulatory treatment \<=6 months before study drug * history or evidence of medical condition associated with chronic liver disease other than chronic hepatitis c * decompensated liver disease * positive for hiv
benefits of outdoor walks in reducing depressive symptoms

Conditions: Depressive Symptoms

Summary: the goal of this clinical trial is to determine whether outdoor walking in different environments-urban or natural-can reduce depressive symptoms among college students. the study also tests whether providing prompts for active engagement during nature walks enhances the benefits compared to unstructured nature walks. participants will be randomly assigned to one of three groups: (1) urban walk, (2) nature walk, or (3) active nature walk with guided interaction. each participant will walk for 30 minutes, twice a week, for 3 weeks, complete questionnaires, and participate in interviews. our primary outcome (phq-9) will be used to test the following two primary hypotheses: * hypothesis 1: participants in both nature walk conditions (combined) will show greater reductions in depressive symptoms (phq-9) than those in the urban walk group. * hypothesis 2: participants in the active nature walk will show greater reductions than those in the regular nature walk.

the investigators aim to compare how walking in different outdoor environments influences depressive symptoms among college students. specifically, the investigators will assess: 1. walking in an urban environment (like a busy city street), 2. walking in a natural environment regularly (e.g., walking without specific guidance), and 3. walking in a natural environment with guided interaction prompts (e.g., noticing birds, listening to sounds, touching flowers). standardized questionnaires will measure changes in depressive symptoms, anxiety, affect, cognitive flexibility, nature connection, and presence across all three groups. the investigators will also explore potential mechanisms behind any observed effects, including interaction patterns, presence, cognitive changes, and emotional responses to the different environments.

Eligibility criteria:
inclusion criteria: * college students in seattle * aged over 18. * having depressive symptoms with self-rated patient health questionnaire-9 (phq-9) scored higher than 5. * normal or corrected-to-normal visual acuity. * no identified hearing impairment. * no history of neurological or mental disorders. exclusion criteria: * receiving clinical psychiatric treatment or psychological counseling. * failing in providing consent form.
perinatal mental health study (pmhs) india

Conditions: Depression; Anxiety; Suicidal Ideation; Somatization; PTSD

Summary: the purpose of this observational study is to improve understanding of mental disorders among perinatal women in india.

the purpose of this observational study is to assess the mental health of perinatal women living in two low-income settings in india. the first phase will explore women's awareness of mental illness and acceptability of screening for mental disorders. the second phase will be a validation study, during which the psychometric properties of screening tools will be assessed against a gold standard. the third stage will comprise a cohort study, during which the prevalence of and risk factors for mental disorders among perinatal and non-perinatal women will be established.

Eligibility criteria:
inclusion criteria: for phase 1 (qualitative study) and phase 2 (validation study): pregnant women: * aged 18 to 45 years * currently pregnant (any trimester) * willing and able to give informed consent post-partum women: * aged 18 to 45 years * currently post-partum (between 1-12 months postpartum) * willing and able to give informed consent non-perinatal women: * aged 18 to 45 years * not currently pregnant and not given birth in the past 12 months * willing and able to give informed consent for phase 3 (prospective cohort study): perinatal women: * aged 18 to 45 years * in early pregnancy (estimated gestational age \<20 weeks) at recruitment * not planning to relocate for the duration of the study period * willing and able to give informed consent * expressed a willingness to continue to participate for the four planned visits non-perinatal women: * aged 18 to 45 years * not currently pregnant and not given birth in the last 12 months * not planning to relocate for the duration of the study period * willing and able to give informed consent * expressed a willingness to continue to participate for the four planned visits exclusion criteria: the participant may not enter the study if: * they have an acutely severe psychiatric illness which impairs their ability to take part in the study * they are not willing or able to provide informed consent other than for current severe psychiatric illness which affects ability to participate in the study, we will not exclude any participant on the basis of current or prior physical, psychological or psychiatric co-morbidities so long as she is willing to participate, her ability to take part is not compromised and her ability to give informed consent is not impaired by these conditions.

Keywords: perinatal post-partum antenatal low- and middle-income country india common mental disorders screening validation prevalence risk factor